vs
镜泰（GNTX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是镜泰的1.3倍（$772.1M vs $586.8M），镜泰净利率更高（16.0% vs 12.7%，领先3.2%），镜泰同比增速更快（562.1% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs 1.2%）
镜泰（Gentex Corp）是美国电子科技企业，面向汽车行业研发生产自动防眩目后视镜、摄像头式驾驶辅助系统等产品，为各类航空市场供应可调光飞机舷窗，同时面向北美消防市场提供光电烟雾探测器、信号设备及HomeLink无线系列产品。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GNTX vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.3倍
$586.8M
营收增速更快
GNTX
高出556.3%
5.9%
净利率更高
GNTX
高出3.2%
12.7%
两年增速更快
RVTY
近两年复合增速
1.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $586.8M | $772.1M |
| 净利润 | $93.8M | $98.4M |
| 毛利率 | 34.0% | — |
| 营业利润率 | 20.1% | 14.5% |
| 净利率 | 16.0% | 12.7% |
| 营收同比 | 562.1% | 5.9% |
| 净利润同比 | -1.1% | 3.9% |
| 每股收益（稀释后） | $0.44 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GNTXRVTY
| Q1 26 | $586.8M | — | ||
| Q4 25 | $644.4M | $772.1M | ||
| Q3 25 | $655.2M | $698.9M | ||
| Q2 25 | $657.9M | $720.3M | ||
| Q1 25 | $576.8M | $664.8M | ||
| Q4 24 | $541.6M | $729.4M | ||
| Q3 24 | $608.5M | $684.0M | ||
| Q2 24 | $572.9M | $691.7M |
净利润GNTXRVTY
| Q1 26 | $93.8M | — | ||
| Q4 25 | $93.3M | $98.4M | ||
| Q3 25 | $101.0M | $46.7M | ||
| Q2 25 | $96.0M | $53.9M | ||
| Q1 25 | $94.9M | $42.2M | ||
| Q4 24 | $87.7M | $94.6M | ||
| Q3 24 | $122.5M | $94.4M | ||
| Q2 24 | $86.0M | $55.4M |
毛利率GNTXRVTY
| Q1 26 | 34.0% | — | ||
| Q4 25 | 34.8% | — | ||
| Q3 25 | 34.4% | 53.6% | ||
| Q2 25 | 34.2% | 54.5% | ||
| Q1 25 | 33.2% | 56.5% | ||
| Q4 24 | 32.5% | — | ||
| Q3 24 | 33.5% | 56.3% | ||
| Q2 24 | 32.9% | 55.7% |
营业利润率GNTXRVTY
| Q1 26 | 20.1% | — | ||
| Q4 25 | 18.6% | 14.5% | ||
| Q3 25 | 18.7% | 11.7% | ||
| Q2 25 | 18.0% | 12.6% | ||
| Q1 25 | 19.6% | 10.9% | ||
| Q4 24 | 16.6% | 16.3% | ||
| Q3 24 | 20.7% | 14.3% | ||
| Q2 24 | 20.1% | 12.4% |
净利率GNTXRVTY
| Q1 26 | 16.0% | — | ||
| Q4 25 | 14.5% | 12.7% | ||
| Q3 25 | 15.4% | 6.7% | ||
| Q2 25 | 14.6% | 7.5% | ||
| Q1 25 | 16.4% | 6.4% | ||
| Q4 24 | 16.2% | 13.0% | ||
| Q3 24 | 20.1% | 13.8% | ||
| Q2 24 | 15.0% | 8.0% |
每股收益（稀释后）GNTXRVTY
| Q1 26 | $0.44 | — | ||
| Q4 25 | $0.43 | $0.86 | ||
| Q3 25 | $0.46 | $0.40 | ||
| Q2 25 | $0.43 | $0.46 | ||
| Q1 25 | $0.42 | $0.35 | ||
| Q4 24 | $0.39 | $0.77 | ||
| Q3 24 | $0.53 | $0.77 | ||
| Q2 24 | $0.37 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $175.0M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | $3.0B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GNTXRVTY
| Q1 26 | $175.0M | — | ||
| Q4 25 | $151.0M | $919.9M | ||
| Q3 25 | $183.4M | $931.4M | ||
| Q2 25 | $141.1M | $991.8M | ||
| Q1 25 | $307.1M | $1.1B | ||
| Q4 24 | $255.6M | $1.2B | ||
| Q3 24 | $200.1M | $1.2B | ||
| Q2 24 | $275.8M | $2.0B |
股东权益GNTXRVTY
| Q1 26 | — | — | ||
| Q4 25 | $2.5B | $7.3B | ||
| Q3 25 | $2.5B | $7.4B | ||
| Q2 25 | $2.4B | $7.6B | ||
| Q1 25 | $2.5B | $7.6B | ||
| Q4 24 | $2.5B | $7.7B | ||
| Q3 24 | $2.4B | $7.9B | ||
| Q2 24 | $2.4B | $7.9B |
总资产GNTXRVTY
| Q1 26 | $3.0B | — | ||
| Q4 25 | $2.9B | $12.2B | ||
| Q3 25 | $2.9B | $12.1B | ||
| Q2 25 | $2.8B | $12.4B | ||
| Q1 25 | $2.8B | $12.4B | ||
| Q4 24 | $2.8B | $12.4B | ||
| Q3 24 | $2.7B | $12.8B | ||
| Q2 24 | $2.7B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流GNTXRVTY
| Q1 26 | — | — | ||
| Q4 25 | $125.5M | $182.0M | ||
| Q3 25 | $147.0M | $138.5M | ||
| Q2 25 | $166.1M | $134.3M | ||
| Q1 25 | $148.5M | $128.2M | ||
| Q4 24 | $154.4M | $174.2M | ||
| Q3 24 | $84.7M | $147.9M | ||
| Q2 24 | $129.3M | $158.6M |
自由现金流GNTXRVTY
| Q1 26 | — | — | ||
| Q4 25 | $99.8M | $161.8M | ||
| Q3 25 | $111.4M | $120.0M | ||
| Q2 25 | $135.0M | $115.5M | ||
| Q1 25 | $111.8M | $112.2M | ||
| Q4 24 | $112.7M | $149.8M | ||
| Q3 24 | $45.4M | $125.6M | ||
| Q2 24 | $97.5M | $136.6M |
自由现金流率GNTXRVTY
| Q1 26 | — | — | ||
| Q4 25 | 15.5% | 21.0% | ||
| Q3 25 | 17.0% | 17.2% | ||
| Q2 25 | 20.5% | 16.0% | ||
| Q1 25 | 19.4% | 16.9% | ||
| Q4 24 | 20.8% | 20.5% | ||
| Q3 24 | 7.5% | 18.4% | ||
| Q2 24 | 17.0% | 19.7% |
资本支出强度GNTXRVTY
| Q1 26 | — | — | ||
| Q4 25 | 4.0% | 2.6% | ||
| Q3 25 | 5.4% | 2.6% | ||
| Q2 25 | 4.7% | 2.6% | ||
| Q1 25 | 6.4% | 2.4% | ||
| Q4 24 | 7.7% | 3.4% | ||
| Q3 24 | 6.5% | 3.3% | ||
| Q2 24 | 5.5% | 3.2% |
现金转化率GNTXRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 1.85× | ||
| Q3 25 | 1.46× | 2.97× | ||
| Q2 25 | 1.73× | 2.49× | ||
| Q1 25 | 1.57× | 3.03× | ||
| Q4 24 | 1.76× | 1.84× | ||
| Q3 24 | 0.69× | 1.57× | ||
| Q2 24 | 1.50× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GNTX
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
